Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) FCF Margin: 2020-2025

Historic FCF Margin for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to -231.33%.

  • Foghorn Therapeutics' FCF Margin rose 4165.00% to -231.33% in Q3 2025 from the same period last year, while for Sep 2025 it was -362.49%, marking a year-over-year increase of 4469.00%. This contributed to the annual value of -448.24% for FY2024, which is 9887.00% down from last year.
  • Foghorn Therapeutics' FCF Margin amounted to -231.33% in Q3 2025, which was up 16.84% from -278.18% recorded in Q2 2025.
  • Foghorn Therapeutics' 5-year FCF Margin high stood at 6,920.59% for Q1 2022, and its period low was -50,565.85% during Q3 2021.
  • In the last 3 years, Foghorn Therapeutics' FCF Margin had a median value of -403.16% in 2025 and averaged -439.23%.
  • Its FCF Margin has fluctuated over the past 5 years, first tumbled by 4,905,803bps in 2021, then spiked by 5,025,961bps in 2022.
  • Over the past 5 years, Foghorn Therapeutics' FCF Margin (Quarterly) stood at 1,655.26% in 2021, then crashed by 235,299bps to -697.73% in 2022, then skyrocketed by 21,969bps to -478.04% in 2023, then tumbled by 39,724bps to -875.28% in 2024, then surged by 4,165bps to -231.33% in 2025.
  • Its FCF Margin was -231.33% in Q3 2025, compared to -278.18% in Q2 2025 and -403.16% in Q1 2025.